These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Approaches to the treatment of chronic myeloid leukemia.
    Author: Savage DG, Goldman JM.
    Journal: Int J Hematol; 1994 Jul; 60(1):1-21. PubMed ID: 7919235.
    Abstract:
    In the past two decades there have been a number of advances in the treatment of chronic myeloid leukemia (CML) in chronic phase. There has been very little progress in the management of advanced disease. Hydroxyurea and interferon-alpha have replaced busulfan as first-line therapy in chronic phase. Hydroxyurea provides excellent control of the disease for periods of months or years and has little toxicity. Interferon-alpha induces a reduction in the Philadelphia chromosome in a substantial minority of patients. Interferon-alpha may also prolong survival. Neither hydroxyurea nor interferon-alpha is able to cure the disease. Patients in chronic phase may be cured by allogeneic bone marrow transplantation (BMT). This procedure has a number of limitations, however, including limited availability, high cost, and substantial morbidity and mortality. Current challenges in BMT are to increase its applicability, to reduce graft-versus-host disease, and to augment graft-versus-leukemia effects. The role of autologous transplantation in CML remains speculative.
    [Abstract] [Full Text] [Related] [New Search]